Can't find what you're looking for?
View all search resultsCan't find what you're looking for?
View all search resultsver 50 million pills containing a combination of paracetamol, caffeine and carisoprodol (PCC) were found by the National Narcotics Agency (BNN) during a raid on a suspected drug factory in Surakarta, Central Java, on Monday.
"We suspected that this was the main source [of the drug operation]," BNN chief Comr. Gen. Budi Waseso said. "All the branches were controlled from here, including Semarang and Sukoharjo."
The Surakarta factory produced up to 50,000 pills a day, he added, and earned up to Rp 2.7 billion (US$200,000) in revenue.
Budi said that, through a special task force formed by the agency to investigate the PCC case, several other factories in Central Java were identified.
"We will uncover the whole network: the financiers, the leaders and the people who were behind them," he said.
Meanwhile, the agency confiscated Monday 13 million pills from a factory in Semarang, Central Java, suspected to have sent supplies used for the pills to Kalimantan and Sulawesi.
Two suspects in the case were named, namely Jhoni, a 38-year-old Semarang resident, and Ronggo, a 52-year-old from Tasikmalaya.
A day earlier, the BNN raided a house that was allegedly used for PCC manufacturing in Surakarta and two houses in nearby Sukoharjo. Seven people were detained, including the owner of the Surakarta house.
Sixty-six teenagers were hospitalized after ingesting PCC pills in Kendari, Southwest Sulawesi, in September. The pills reportedly caused them to act differently before they fell unconscious. (kmt/rin)
Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.
Thank you for sharing your thoughts. We appreciate your feedback.
Quickly share this news with your network—keep everyone informed with just a single click!
Share the best of The Jakarta Post with friends, family, or colleagues. As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed!
Get the best experience—faster access, exclusive features, and a seamless way to stay updated.